{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:18:16Z","timestamp":1792700296397,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Normal cell <jats:italic>BRCA1<\/jats:italic> epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have <jats:italic>BRCA1<\/jats:italic> epimutations as their underlying cause is unknown. Neither are the time of occurrence and the potential inheritance patterns of <jats:italic>BRCA1<\/jats:italic> epimutations established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To address these questions, we analyzed <jats:italic>BRCA1<\/jats:italic> methylation status in breast cancer tissue and matched white blood cells (WBC) from 408 patients with 411 primary breast cancers, including 66 TNBCs, applying a highly sensitive sequencing assay, allowing allele-resolved methylation assessment. Furthermore, to assess the time of origin and the characteristics of normal cell <jats:italic>BRCA1<\/jats:italic> methylation, we analyzed umbilical cord blood of 1260 newborn girls and 200 newborn boys. Finally, we assessed <jats:italic>BRCA1<\/jats:italic> methylation status among 575 mothers and 531 fathers of girls with (<jats:italic>n<\/jats:italic>\u2009=\u2009102) and without (<jats:italic>n<\/jats:italic>\u2009=\u2009473) <jats:italic>BRCA1<\/jats:italic> methylation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found concordant tumor and mosaic WBC <jats:italic>BRCA1<\/jats:italic> epimutations in 10 out of 66 patients with TNBC and in four out of six patients with estrogen receptor (ER)-low expression (&lt;\u200910%) tumors (combined: 14 out of 72; 19.4%; 95% CI 11.1\u201330.5). In contrast, we found concordant WBC and tumor methylation in only three out of 220 patients with 221 ER\u2009\u2265\u200910% tumors and zero out of 114 patients with 116 HER2-positive tumors. Intraindividually, <jats:italic>BRCA1<\/jats:italic> epimutations affected the same allele in normal and tumor cells. Assessing <jats:italic>BRCA1<\/jats:italic> methylation in umbilical WBCs from girls, we found mosaic, predominantly monoallelic <jats:italic>BRCA1<\/jats:italic> epimutations, with qualitative features similar to those in adults, in 113\/1260 (9.0%) of individuals, but no correlation to <jats:italic>BRCA1<\/jats:italic> methylation status either in mothers or fathers. A significantly lower fraction of newborn boys carried <jats:italic>BRCA1<\/jats:italic> methylation (9\/200; 4.5%) as compared to girls (<jats:italic>p<\/jats:italic>\u2009=\u20090.038). Similarly, WBC <jats:italic>BRCA1<\/jats:italic> methylation was found less common among fathers (16\/531; 3.0%), as compared to mothers (46\/575; 8.0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest prenatal <jats:italic>BRCA1<\/jats:italic> epimutations might be the underlying cause of around 20% of TNBC and low-ER expression breast cancers. Such constitutional mosaic <jats:italic>BRCA1<\/jats:italic> methylation likely arise through gender-related mechanisms in utero, independent of Mendelian inheritance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13073-023-01262-8","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:02:12Z","timestamp":1701820932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4934","authenticated-orcid":false,"given":"Oleksii","family":"Nikolaienko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P.","family":"Eikesdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4775-0661","authenticated-orcid":false,"given":"Elisabet","family":"Ognedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-4081","authenticated-orcid":false,"given":"Bj\u00f8rnar","family":"Gilje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil S.","family":"Blix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Espelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7760-5396","authenticated-orcid":false,"given":"Emiel A. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-3031","authenticated-orcid":false,"given":"Synn\u00f8ve","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9775-3880","authenticated-orcid":false,"given":"Laura","family":"Minsaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beryl","family":"Leirvaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7453-1027","authenticated-orcid":false,"given":"Reidun","family":"Lillest\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-1655","authenticated-orcid":false,"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-6303","authenticated-orcid":false,"given":"Per E.","family":"L\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"1262_CR1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148\u201359.","journal-title":"N Engl J Med"},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"e59064","DOI":"10.1371\/journal.pone.0059064","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, Liu Y, Wang D, Sun G, Zhao Y. MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PLoS ONE. 2013;8:e59064.","journal-title":"PLoS ONE"},{"issue":"6","key":"1262_CR3","first-page":"1","volume":"7","author":"T Walsh","year":"2021","unstructured":"Walsh T, Gulsuner S, Lee MK, Troester MA, Olshan AF, Earp HS, Perou CM, King MC. Inherited predisposition to breast cancer in the Carolina Breast Cancer Study. Npj Breast Cancer. 2021;7(6):1\u20136.","journal-title":"Npj Breast Cancer."},{"key":"1262_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"CL Hu","year":"2021","unstructured":"Hu CL, Hart SN, Gnanaolivu R, Huang HY, Lee KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384:440\u201351.","journal-title":"N Engl J Med"},{"key":"1262_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, Parsons MT, Fortuno C, Wang Q, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021;384:428\u201339.","journal-title":"N Engl J Med"},{"key":"1262_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-008-0121-3","volume":"116","author":"T Kontorovich","year":"2009","unstructured":"Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1\/BRCA2 mutation carriers. Breast Cancer Res Treat. 2009;116:195\u2013200.","journal-title":"Breast Cancer Res Treat"},{"issue":"3747","key":"1262_CR7","first-page":"3741","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersward C, Karlsson A, Mitra S, Nimeus E, Holm K, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(3747):3741\u20133715.","journal-title":"Nat Commun."},{"key":"1262_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240\u20139.","journal-title":"Ann Oncol"},{"issue":"art number 4026","key":"1262_CR9","first-page":"1","volume":"4","author":"JM Cunningham","year":"2014","unstructured":"Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Scientific Reports. 2014;4(art number 4026):1\u20137.","journal-title":"Scientific Reports"},{"key":"1262_CR10","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1093\/nar\/28.17.3233","volume":"28","author":"JC Rice","year":"2000","unstructured":"Rice JC, Futscher BW. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 2000;28:3233\u20139.","journal-title":"Nucleic Acids Res"},{"key":"1262_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/gcc.20833","volume":"50","author":"SA Joosse","year":"2011","unstructured":"Joosse SA, Brandwijk KIM, Mulder L, Wesseling J, Hannemann J, Nederlof PM. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosom Cancer. 2011;50:71\u201381.","journal-title":"Genes Chromosom Cancer"},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"326-+","DOI":"10.7326\/M17-0101","volume":"168","author":"PE L\u00f8nning","year":"2018","unstructured":"L\u00f8nning PE, Berge EO, Bjornslett M, Minsaas L, Chrisanthar R, Hoberg-Vetti H, Dulary C, Busato F, Bjorneklett S, Eriksen C, et al. white blood cell BRCA1 promoter methylation status and ovarian cancer risk. Ann Intern Med. 2018;168:326-+.","journal-title":"Ann Intern Med"},{"issue":"14","key":"1262_CR13","first-page":"1","volume":"2022","author":"F Menghi","year":"1926","unstructured":"Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 1926;2022(14):1\u201318.","journal-title":"Sci Transl Med."},{"key":"1262_CR14","doi-asserted-by":"publisher","first-page":"628-+","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628-+.","journal-title":"Nat Med"},{"key":"1262_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.15698\/cst2019.04.183","volume":"3","author":"PE L\u00f8nning","year":"2019","unstructured":"L\u00f8nning PE, Eikesdal HP, Loes IM, Knappskog S. Constitutional mosaic epimutations - a hidden cause of cancer? Cell Stress. 2019;3:118\u201335.","journal-title":"Cell Stress"},{"key":"1262_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajhg.2018.07.002","volume":"103","author":"DGR Evans","year":"2018","unstructured":"Evans DGR, van Veen EM, Byers HJ, Wallace AJ, Ellingford JM, Beaman G, Santoyo-Lopez J, Aitman TJ, Eccles DM, Lalloo FI, Smith MJ, Newman WG. A dominantly inherited 5\u2032 UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet. 2018;103:213\u201320.","journal-title":"Am J Hum Genet"},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-020-00175-4","volume":"19","author":"A Laner","year":"2020","unstructured":"Laner A, Benet-Pages A, Neitzel B, Holinski-Feder E. Analysis of 3297 individuals suggests that the pathogenic germline 5\u2032-UTR variant BRCA1 c.-107A > T is not common in south-east Germany. Familial Cancer. 2020;19:211\u20133.","journal-title":"Familial Cancer"},{"key":"1262_CR18","doi-asserted-by":"publisher","unstructured":"de Jong VMT, Pruntel R, Steenbruggen TG, Bleeker FE, Nederlof P, Hogervorst FBL, Linn SC: Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation. Familial Cancer 2022. https:\/\/doi.org\/10.1007\/s10689-10022-00314-z.","DOI":"10.1007\/s10689-10022-00314-z"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/ijc.32655","volume":"146","author":"K Prajzendanc","year":"2020","unstructured":"Prajzendanc K, Domagala P, Hybiak J, Rys J, Huzarski T, Szwiec M, Tomiczek-Szwiec J, Redelbach W, Sejda A, Gronwald J, et al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. Int J Cancer. 2020;146:1293\u20138.","journal-title":"Int J Cancer"},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr1858:1-8","volume":"10","author":"C Snell","year":"2008","unstructured":"Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008;10:R12. https:\/\/doi.org\/10.1186\/bcr1858:1-8.","journal-title":"Breast Cancer Res"},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1940-6207.CAPR-10-0212","volume":"4","author":"EM Wong","year":"2011","unstructured":"Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res. 2011;4:23\u201333.","journal-title":"Cancer Prev Res"},{"key":"1262_CR22","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1093\/hmg\/dds308","volume":"21","author":"T Hansmann","year":"2012","unstructured":"Hansmann T, Pliushch G, Leubner M, Kroll P, Endt D, Gehrig A, Preisler-Adams S, Wieacker P, Haaf T. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet. 2012;21:4669\u201379.","journal-title":"Hum Mol Genet"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-010-1188-1","volume":"129","author":"T Iwamoto","year":"2011","unstructured":"Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat. 2011;129:69\u201377.","journal-title":"Breast Cancer Res Treat"},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.cca.2011.04.027","volume":"412","author":"R Bosviel","year":"2011","unstructured":"Bosviel R, Michard E, Lavediaux G, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clin Chim Acta. 2011;412:1472\u20135.","journal-title":"Clin Chim Acta"},{"issue":"58","key":"1262_CR25","first-page":"1","volume":"11","author":"J Azzollini","year":"2019","unstructured":"Azzollini J, Pesenti C, Pizzamiglio S, Fontana L, Guarino C, Peissel B, Plebani M, Tabano S, Sirchia SM, Colapietro P, et al. Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. Cancers. 2019;11(58):1\u201315.","journal-title":"Cancers."},{"key":"1262_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1001\/jamaoncol.2022.3846","volume":"8","author":"PE L\u00f8nning","year":"2022","unstructured":"L\u00f8nning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, Anderson GL, Prentice RL, Chlebowski RT, Knappskog S. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. JAMA Oncol. 2022;8:1579\u201387.","journal-title":"JAMA Oncol"},{"key":"1262_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/oxfordjournals.aje.a114174","volume":"122","author":"P Bruzzi","year":"1985","unstructured":"Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk-factors using case-control data. Am J Epidemiol. 1985;122:904\u201313.","journal-title":"Am J Epidemiol"},{"key":"1262_CR28","doi-asserted-by":"publisher","first-page":"e19249","DOI":"10.1371\/journal.pone.0019249","volume":"6","author":"R Chrisanthar","year":"2011","unstructured":"Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjonsberg G, Aas T, et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS ONE. 2011;6:e19249.","journal-title":"PLoS ONE"},{"issue":"86","key":"1262_CR29","first-page":"1","volume":"14","author":"A Venizelos","year":"2022","unstructured":"Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, et al. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Med. 2022;14(86):1\u201318.","journal-title":"Genome Med."},{"key":"1262_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ije\/dyw029","volume":"45","author":"P Magnus","year":"2016","unstructured":"Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Hoiseth G, Knudsen GP, et al. Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45:382\u20138.","journal-title":"Int J Epidemiol"},{"key":"1262_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/15592294.2016.1214782","volume":"11","author":"K Gervin","year":"2016","unstructured":"Gervin K, Page CM, Aass HC, Jansen MA, Fjeldstad HE, Andreassen BK, Duijts L, van Meurs JB, van Zelm MC, Jaddoe VW, et al. Cell type specific DNA methylation in cord blood: a 450K-reference data set and cell count-based validation of estimated cell type composition. Epigenetics. 2016;11:690\u20138.","journal-title":"Epigenetics"},{"key":"1262_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"1262_CR33","doi-asserted-by":"publisher","first-page":"751-+","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751-+.","journal-title":"Nat Med"},{"key":"1262_CR34","doi-asserted-by":"publisher","first-page":"D835","DOI":"10.1093\/nar\/gkz972","volume":"48","author":"MJ Landrum","year":"2020","unstructured":"Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu BS, Hart J, Hoffman D, Jang W, Kaur K, Liu CL, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48:D835\u201344.","journal-title":"Nucleic Acids Res"},{"issue":"087","key":"1262_CR35","first-page":"1","volume":"12","author":"O Nikolaienko","year":"2023","unstructured":"Nikolaienko O, L\u00f8nning PE, Knappskog S. epialleleR: an R\/BioC package for sensitive allele-specific methylation analysis in NGS data. GigaScience. 2023;12(087):1\u201314.","journal-title":"GigaScience."},{"key":"1262_CR36","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","volume":"30","author":"T Iwamoto","year":"2012","unstructured":"Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi WW, Qi Y, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30:729\u201334.","journal-title":"J Clin Oncol"},{"key":"1262_CR37","doi-asserted-by":"publisher","first-page":"1330-+","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysa SD, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 2019;177:1330-+.","journal-title":"Cell"},{"key":"1262_CR38","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M. Molecular origins of cancer: epigenetics in cancer. N Engl J Med. 2008;358:1148\u201359.","journal-title":"N Engl J Med"},{"key":"1262_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"issue":"7148","key":"1262_CR40","first-page":"1","volume":"23","author":"R Della Monica","year":"2022","unstructured":"Della Monica R, Cuomo M, Buonaiuto M, Costabile D, Franca RA, De Caro MD, Catapano G, Chiariotti L, Visconti R. MGMT and whole-genome DNA methylation impacts on diagnosis, prognosis and therapy of glioblastoma multiforme. Int J Mol Sci. 2022;23(7148):1\u201315.","journal-title":"Int J Mol Sci."},{"key":"1262_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrc1279","volume":"4","author":"AP Feinberg","year":"2004","unstructured":"Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143\u201353.","journal-title":"Nat Rev Cancer"},{"key":"1262_CR42","first-page":"3925","volume":"62","author":"I Gazzoli","year":"2002","unstructured":"Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Can Res. 2002;62:3925\u20138.","journal-title":"Can Res"},{"key":"1262_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa064522","volume":"356","author":"MP Hitchins","year":"2007","unstructured":"Hitchins MP, Wong JJL, Suthers G, Suter CM, Martin DIK, Hawkins NJ, Ward RL. Brief report: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007;356:697\u2013705.","journal-title":"N Engl J Med"},{"key":"1262_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc4001","volume":"15","author":"MP Hitchins","year":"2015","unstructured":"Hitchins MP. Constitutional epimutation as a mechanism for cancer causality and heritability? Nature Rev Cancer. 2015;15:181\u201394.","journal-title":"Nature Rev Cancer"},{"key":"1262_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10689-013-9613-3","volume":"12","author":"MP Hitchins","year":"2013","unstructured":"Hitchins MP. The role of epigenetics in Lynch syndrome. Fam Cancer. 2013;12:189\u2013205.","journal-title":"Fam Cancer"},{"issue":"99","key":"1262_CR46","first-page":"1","volume":"10","author":"N Al-Moghrabi","year":"2018","unstructured":"Al-Moghrabi N, Al-Showimi M, Al-Yousef N, Al-Shahrani B, Karakas B, Alghofaili L, Almubarak H, Madkhali S, Al Humaidan H. Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters. Clin Epigenetics. 2018;10(99):1\u201310.","journal-title":"Clin Epigenetics."},{"key":"1262_CR47","doi-asserted-by":"publisher","first-page":"297-+","DOI":"10.1016\/j.ccell.2019.01.004","volume":"35","author":"K Skvortsova","year":"2019","unstructured":"Skvortsova K, Masle-Farquhar E, Luu PL, Song JZ, Qu WJ, Zotenko E, Gould CM, Du Q, Peters TJ, Colino-Sanguino Y, et al. DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation patterns. Cancer Cell. 2019;35:297-+.","journal-title":"Cancer Cell"},{"key":"1262_CR48","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/2159-8290.CD-21-1110","volume":"12","author":"F Pareja","year":"2022","unstructured":"Pareja F, Ptashkin RN, Brown DN, Derakhshan F, Selenica P, da Silva EM, Gazzo AM, Da Cruz PA, Breen K, Shen R, et al. Cancer-causative mutations occurring in early embryogenesis. Cancer Discov. 2022;12:949\u201357.","journal-title":"Cancer Discov"},{"key":"1262_CR49","doi-asserted-by":"publisher","first-page":"387-+","DOI":"10.1038\/s41586-021-03790-y","volume":"597","author":"THH Coorens","year":"2021","unstructured":"Coorens THH, Moore L, Robinson PS, Sanghvi R, Christopher J, Hewinson J, Przybilla MJ, Lawson ARJ, Chapman MS, Cagan A, et al. Extensive phylogenies of human development inferred from somatic mutations. Nature. 2021;597:387-+.","journal-title":"Nature"},{"issue":"Suppl","key":"1262_CR50","first-page":"S6","volume":"70","author":"B Rack","year":"2010","unstructured":"Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann MW, Sommer HL, Pantel K, Friese K, Janni W. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Ca Res. 2010;70(Suppl):S6-5, 93s.","journal-title":"Ca Res."},{"key":"1262_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"issue":"166583","key":"1262_CR52","first-page":"1","volume":"1896","author":"YZ Li","year":"2023","unstructured":"Li YZ, Fan ZY, Meng YF, Liu SJ, Zhan HX. Blood-based DNA methylation signatures in cancer: a systematic review. Biochimica Et Biophysica Acta-Mol Basis Dis. 2023;1896(166583):1\u201314.","journal-title":"Biochimica Et Biophysica Acta-Mol Basis Dis."},{"issue":"art number 86","key":"1262_CR53","first-page":"1","volume":"13","author":"EA Houseman","year":"2012","unstructured":"Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture distribution. Bmc Bioinform. 2012;13(art number 86):1\u201316.","journal-title":"Bmc Bioinform"},{"issue":"art no 21","key":"1262_CR54","first-page":"1","volume":"7","author":"BL Fridley","year":"2014","unstructured":"Fridley BL, Armasu SM, Cicek MS, Larson MC, Wang C, Winham SJ, Kalli KR, Koestler DC, Rider DN, Shridhar V, et al. Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. Bmc Med Genomics. 2014;7(art no 21):1\u201312.","journal-title":"Bmc Med Genomics"},{"key":"1262_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0041361","volume":"7","author":"LE Reinius","year":"2012","unstructured":"Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, Soderhall C, Scheynius A, Kere J. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS ONE. 2012;7:1\u201313.","journal-title":"PLoS ONE"},{"key":"1262_CR56","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4161\/epi.6.9.16401","volume":"6","author":"DJ Martino","year":"2011","unstructured":"Martino DJ, Tulic MK, Gordon L, Hodder M, Richman T, Metcalfe J, Prescott SL, Saffery R. Evidence for age-related and individual-specific changes in DNA methylation profile of mononuclear cells during early immune development in humans. Epigenetics. 2011;6:1085\u201394.","journal-title":"Epigenetics"},{"key":"1262_CR57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2018.30","volume":"15","author":"M Widschwendter","year":"2018","unstructured":"Widschwendter M, Jones A, Evans I, Reiser D, Dillner J, Sundstrom K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2018;15:292\u2013309.","journal-title":"Nat Rev Clin Oncol"},{"issue":"449","key":"1262_CR58","first-page":"1","volume":"13","author":"JE Barrett","year":"2022","unstructured":"Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim Y-N, Franchi D, et al. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. 2022;13(449):1\u201314.","journal-title":"Nat Commun."},{"issue":"448","key":"1262_CR59","first-page":"1","volume":"13","author":"JE Barrett","year":"2022","unstructured":"Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjorge L, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022;13(448):1\u201312.","journal-title":"Nat Commun."},{"key":"1262_CR60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2023.02.017","volume":"171","author":"MP Hitchins","year":"2023","unstructured":"Hitchins MP, Alvarez R, Zhou L, Aguirre F, Damaso E, Pineda M, Capella G, Wong JJL, Yuan X, Ryan SR, et al. MLH1-methylated endometrial cancer under 60 years of age as the \u201csentinel\u201d cancer in female carriers of high-risk constitutional MLH1 epimutation. Gynecol Oncol. 2023;171:129\u201340.","journal-title":"Gynecol Oncol"},{"issue":"171","key":"1262_CR61","first-page":"1","volume":"11","author":"E Damaso","year":"2019","unstructured":"Damaso E, Canet-Hermida J, Vargas-Parra G, Velasco A, Marin F, Darder E, del Valle J, Fernandez A, Izquierdo A, Mateu G, et al. Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. Clin Epigenetics. 2019;11(171):1\u201310.","journal-title":"Clin Epigenetics."},{"key":"1262_CR62","doi-asserted-by":"crossref","unstructured":"Nikolaienko O, Knappskog S, L\u00f8nning PE: Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. NCBI Gene Expression Omnibus; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE243966. Accessed 26 Oct 2023.","DOI":"10.1101\/2023.05.14.23289949"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-023-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-023-01262-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-023-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:03:17Z","timestamp":1701820997000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-023-01262-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1186\/s13073-023-01262-8","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"9 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants in the clinical studies provided written informed consent, and the current study is covered by each consent. All studies were approved by the Regional Ethics Committee (reference numbers: 273\/96\u201382.96, 06\/3077 and 2015\/1493). Each part of the study conformed to the Helsinki Declaration of research on humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Research Funding (<i>to Institution<\/i>): Astellas Oncology (BG), AstraZeneca (HPE, BG, SK, PEL, ESB), Celgene (BG), Novartis (HPE, PEL), Pfizer (HPE, SK, BG, PEL).Honoraria: Amgen (HPE), AstraZeneca (HPE, BG, TA, EAMJ, SK, PEL), Abbvie (PEL), Bristol-Myers-Squibb (HPE, JG), Dagens Medisin (HPE, PEL), Eli Lilly (JG), HAI Interaktiv AS (HPE), MSD (JG), Novartis (HPE, JG, SK), Pfizer (HPE, EAJ, SK), Pierre Fabre (HPE, JG, SK, PEL), Roche (HPE, BG, TA, PEL).Consulting or Advisory Role: Aptitude Health (HPE), Astellas Oncology (BG), AstraZeneca (ESB, JG, PEL), Daiichi Sankyo (ESB, HPE), Eli Lilly (ESB, HPE, JG), Gilead (ESB), Laboratorios Farmaceuticos Rovi (PEL), MSD (ESB, HPE, JG), Novartis (ESB, HPE, JG), Pfizer (HPE), Pierre Fabre (HPE), Roche (HPE, BG).Expert Testimony: Pfizer (HPE).Travel, Accomodations, Expenses: AstraZeneca (HPE), Pierre Fabre (HPE, BG, PEL), Roche (BG).Speakers\u2019 Bureau: Akademikonferens (PEL), Aptitude Health (PEL), AstraZeneca (JG), Bristol-Myers-Squibb (JG), MSD (JG), Novartis (JG), Pfizer (JG), Pierre Fabre (JG).Patents, Royalties, Other Intellectual Property: Patent EP2389450 A1 (SK), Patent WO 2012\/010661 (SK), Cytovation (PEL).All remaining authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}